{"id":7008,"date":"2025-02-28T10:46:18","date_gmt":"2025-02-28T10:46:18","guid":{"rendered":"https:\/\/itbusinesstoday.com\/?p=7008"},"modified":"2025-05-06T07:51:53","modified_gmt":"2025-05-06T07:51:53","slug":"eisai-enters-into-license-agreement-with-sciclone-for-development-and-commercialization-of-tasulgratinib-in-china-hong-kong-macau-and-taiwan","status":"publish","type":"post","link":"https:\/\/itbusinesstoday.com\/ja\/health-tech\/pharma\/eisai-enters-into-license-agreement-with-sciclone-for-development-and-commercialization-of-tasulgratinib-in-china-hong-kong-macau-and-taiwan\/","title":{"rendered":"\u4e2d\u56fd\u3001\u9999\u6e2f\u3001\u30de\u30ab\u30aa\u3001\u53f0\u6e7e\u306b\u304a\u3051\u308b\u30bf\u30b9\u30eb\u30b0\u30e9\u30c1\u30cb\u30d6\u306e\u958b\u767a\u304a\u3088\u3073\u5546\u696d\u5316\u306b\u95a2\u3059\u308b\u30b5\u30a4\u30af\u30ed\u30f3\u793e\u3068\u306e\u30e9\u30a4\u30bb\u30f3\u30b9\u5951\u7d04\u7de0\u7d50\u306b\u3064\u3044\u3066"},"content":{"rendered":"<p>\u30a8\u30fc\u30b6\u30a4\u682a\u5f0f\u4f1a\u793e\uff08\u672c\u793e\uff1a\u6771\u4eac\u90fd\u3001\u793e\u9577\uff1a\u5185\u85e4\u6674\u592b\uff09\u306f\u3001\u81ea\u793e\u5275\u88fd\u306e\u9078\u629e\u7684\u7dda\u7dad\u82bd\u7d30\u80de\u5897\u6b96\u56e0\u5b50\u53d7\u5bb9\u4f53\uff08FGFR\uff09\u30c1\u30ed\u30b7\u30f3\u30ad\u30ca\u30fc\u30bc\u963b\u5bb3\u5264\u3067\u3042\u308b\u30b3\u30cf\u30af\u9178\u30bf\u30b9\u30eb\u30b0\u30e9\u30c1\u30cb\u30d6\u306b\u3064\u3044\u3066\u3001\u4e2d\u56fd\u3001\u9999\u6e2f\u3001\u30de\u30ab\u30aa\u3001\u53f0\u6e7e\u306b\u304a\u3051\u308b\u72ec\u5360\u7684\u958b\u767a\u30fb\u8ca9\u58f2\u6a29\u3092\u4ed8\u4e0e\u3059\u308b\u30e9\u30a4\u30bb\u30f3\u30b9\u5951\u7d04\u3092SciClone Pharmaceuticals Limited\u3068\u7de0\u7d50\u3057\u307e\u3057\u305f\u3002 <a href=\"https:\/\/www.eisai.com\/\">\u30a8\u30fc\u30b6\u30a4<\/a> \u306f\u3001\u30bf\u30b9\u30eb\u30b0\u30e9\u30c1\u30cb\u30d6\u306b\u95a2\u3059\u308b\u5168\u4e16\u754c\u3067\u306e\u6a29\u5229\u3092\u4fdd\u6301\u3057\u3001\u65e2\u306b\u4e0a\u5e02\u3055\u308c\u3066\u3044\u308b\u65e5\u672c\u3067\u306f\u5f15\u304d\u7d9a\u304d\u88fd\u9020\u30fb\u8ca9\u58f2\u3092\u884c\u3044\u307e\u3059\u3002<\/p>\n<p>\u672c\u5951\u7d04\u306b\u57fa\u3065\u304d\u3001\u5f53\u793e\u306f\u5951\u7d04\u4e00\u6642\u91d1\u3001\u958b\u767a\u304a\u3088\u3073\u898f\u5236\u4e0a\u306e\u30de\u30a4\u30eb\u30b9\u30c8\u30f3\u3001\u767a\u58f2\u5f8c\u306f\u8ca9\u58f2\u30de\u30a4\u30eb\u30b9\u30c8\u30f3\u304a\u3088\u3073\u8ca9\u58f2\u53ce\u5165\u306b\u5fdc\u3058\u305f\u4e00\u5b9a\u306e\u30ed\u30a4\u30e4\u30eb\u30c6\u30a3\u3092\u53d7\u3051\u53d6\u308a\u307e\u3059\u3002<\/p>\n<h4><strong>\u3053\u3061\u3089\u3082\u304a\u8aad\u307f\u304f\u3060\u3055\u3044\uff1a <a class=\"p-url\" href=\"https:\/\/itbusinesstoday.com\/ja\/health-tech\/pharma\/cardinal-health-co-ltd-launches-latest-enteral-nutrition-pump\/\" rel=\"bookmark\">\u30ab\u30fc\u30c7\u30a3\u30ca\u30eb\u30fb\u30d8\u30eb\u30b9\u682a\u5f0f\u4f1a\u793e\u304c\u6700\u65b0\u306e\u7d4c\u8178\u6804\u990a\u30dd\u30f3\u30d7\u3092\u767a\u58f2<\/a><\/strong><\/h4>\n<p>\u30bf\u30b9\u30eb\u30b0\u30e9\u30c1\u30cb\u30d6\u306f\u3001FGFR1\u3001FGFR2\u3001FGFR3\u306b\u5bfe\u3057\u3066\u9078\u629e\u7684\u963b\u5bb3\u6d3b\u6027\u3092\u793a\u3059\u65b0\u898f\u7d4c\u53e3\u6295\u4e0e\u578b\u30c1\u30ed\u30b7\u30f3\u30ad\u30ca\u30fc\u30bc\u963b\u5bb3\u5264\u3067\u3059\u3002\u65e5\u672c\u3067\u306f\u3001\u300c\u5316\u5b66\u7642\u6cd5\u65bd\u884c\u5f8c\u306b\u9032\u884c\u3057\u305f\u5207\u9664\u4e0d\u80fd\u306aFGFR2\u878d\u5408\u907a\u4f1d\u5b50\u967d\u6027\u306e\u80c6\u9053\u304c\u3093\u300d\u3092\u52b9\u80fd\u30fb\u52b9\u679c\u3068\u3057\u3066\u627f\u8a8d\u3055\u308c\u30012024\u5e7411\u6708\u3088\u308a\u767a\u58f2\u3055\u308c\u3066\u3044\u307e\u3059\u3002\u307e\u305f\u3001\u30a8\u30b9\u30c8\u30ed\u30b2\u30f3\u53d7\u5bb9\u4f53\u967d\u6027\u3001HER2\u9670\u6027\u306e\u4e73\u304c\u3093\u60a3\u8005\u3092\u5bfe\u8c61\u3068\u3057\u305f\u7b2cI\u76f8\u81e8\u5e8a\u8a66\u9a13\u304c\u65e5\u672c\u3067\u9032\u884c\u4e2d\u3067\u3059\u3002<\/p>\n<p>\u30b5\u30a4\u30af\u30ed\u30f3\u306f\u3001\u304c\u3093\u304a\u3088\u3073\u91cd\u7be4\u306a\u611f\u67d3\u75c7\u6cbb\u7642\u85ac\u306e\u958b\u767a\u30fb\u5546\u696d\u5316\u306e\u305f\u3081\u306e\u7d71\u5408\u7684\u306a\u30d7\u30e9\u30c3\u30c8\u30d5\u30a9\u30fc\u30e0\u3092\u6709\u3059\u308b\u4e16\u754c\u7684\u306a\u30d0\u30a4\u30aa\u533b\u85ac\u54c1\u4f01\u696d\u3067\u3042\u308a\u3001\u4e2d\u83ef\u570f\u306b\u304a\u3044\u3066\u5f37\u529b\u306a\u30d7\u30ec\u30bc\u30f3\u30b9\u3092\u6709\u3057\u3066\u3044\u307e\u3059\u3002\u4eca\u56de\u306e\u30e9\u30a4\u30bb\u30f3\u30b9\u5951\u7d04\u306b\u3088\u308a\u3001\u30e9\u30a4\u30bb\u30f3\u30b9\u8a31\u8afe\u5730\u57df\u306b\u304a\u3044\u3066\u672c\u5264\u306e\u4fa1\u5024\u3092\u6700\u5927\u5316\u3057\u3001\u5fc5\u8981\u3068\u3057\u3066\u3044\u308b\u60a3\u8005\u3055\u3093\u306b\u4e00\u65e5\u3082\u65e9\u304f\u8ca2\u732e\u3057\u305f\u3044\u3068\u8003\u3048\u3066\u3044\u307e\u3059\u3002<\/p>\n<p><strong>\u30bd\u30fc\u30b9 <a href=\"https:\/\/www.acnnewswire.com\/press-release\/japanese\/96516\/%E3%82%A8%E3%83%BC%E3%82%B6%E3%82%A4%E3%80%81%E7%B7%9A%E7%B6%AD%E8%8A%BD%E7%B4%B0%E8%83%9E%E5%A2%97%E6%AE%96%E5%9B%A0%E5%AD%90%E5%8F%97%E5%AE%B9%E4%BD%93%EF%BC%88fgfr%EF%BC%89%E9%81%B8%E6%8A%9E%E7%9A%84%E3%83%81%E3%83%AD%E3%82%B7%E3%83%B3%E3%82%AD%E3%83%8A%E3%83%BC%E3%82%BC%E9%98%BB%E5%AE%B3%E5%89%A4%E3%82%BF%E3%82%B9%E3%83%AB%E3%82%B0%E3%83%A9%E3%83%81%E3%83%8B%E3%83%96%E3%81%AB%E3%81%A4%E3%81%84%E3%81%A6%E4%B8%AD%E5%9B%BD%E3%83%BB%E9%A6%99%E6%B8%AF%E3%83%BB%E3%83%9E%E3%82%AB%E3%82%AA%E3%83%BB%E5%8F%B0%E6%B9%BE%E3%81%A7%E3%81%AE%E9%96%8B%E7%99%BA%E3%83%BB%E8%B2%A9%E5%A3%B2%E3%81%AB%E9%96%A2%E3%81%99%E3%82%8B%E3%83%A9%E3%82%A4%E3%82%BB%E3%83%B3%E3%82%B9%E5%A5%91%E7%B4%84%E3%82%92sciclone%E3%81%A8%E7%B7%A0%E7%B5%90\">ACNN NewsWire<\/a><\/strong><\/p>","protected":false},"excerpt":{"rendered":"<p>Eisai Co., Ltd. announced that it has signed a license agreement with SciClone Pharmaceuticals Limited to grant exclusive rights to develop and sell tasulgratinib succinate, an in-house developed selective fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitor, in China, Hong Kong, Macau and Taiwan. Eisai will retain the rights to tasulgratinib worldwide outside the license territory, and will continue to manufacture and sell the drug in Japan, where it has already been launched. Under this agreement, the Company will receive an upfront payment, as well as development and regulatory milestone payments, and, once launched, sales milestone payments and certain royalties based on sales revenue. Also Read: Cardinal Health Co., Ltd. [&hellip;]<\/p>\n","protected":false},"author":4,"featured_media":7044,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_bbp_topic_count":0,"_bbp_reply_count":0,"_bbp_total_topic_count":0,"_bbp_total_reply_count":0,"_bbp_voice_count":0,"_bbp_anonymous_reply_count":0,"_bbp_topic_count_hidden":0,"_bbp_reply_count_hidden":0,"_bbp_forum_subforum_count":0,"wprm-recipe-roundup-name":"","wprm-recipe-roundup-description":"","postBodyCss":"","postBodyMargin":[],"postBodyPadding":[],"postBodyBackground":{"backgroundType":"classic","gradient":""},"footnotes":""},"categories":[89,207,237,182],"tags":[1715,424,1716,1714,1713],"ppma_author":[205],"class_list":{"0":"post-7008","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-health-tech","8":"category-international","9":"category-news","10":"category-pharma","11":"tag-eisai","12":"tag-pharma","13":"tag-sciclone","14":"tag-tasulgratinib","15":"tag-tyrosine-kinase-inhibitor"},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.2 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Eisai Licenses Tasulgratinib to SciClone for Greater China<\/title>\n<meta name=\"description\" content=\"Eisai has signed an agreement with SciClone Pharmaceuticals Limited to grant exclusive rights to develop and sell tasulgratinib succinate.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/itbusinesstoday.com\/ja\/health-tech\/eisai-enters-into-license-agreement-with-sciclone-for-development-and-commercialization-of-tasulgratinib-in-china-hong-kong-macau-and-taiwan\/\" \/>\n<meta property=\"og:locale\" content=\"ja_JP\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Eisai Licenses Tasulgratinib to SciClone for Greater China\" \/>\n<meta property=\"og:description\" content=\"Eisai has signed an agreement with SciClone Pharmaceuticals Limited to grant exclusive rights to develop and sell tasulgratinib succinate.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/itbusinesstoday.com\/ja\/health-tech\/eisai-enters-into-license-agreement-with-sciclone-for-development-and-commercialization-of-tasulgratinib-in-china-hong-kong-macau-and-taiwan\/\" \/>\n<meta property=\"og:site_name\" content=\"itbusinesstoday\" \/>\n<meta property=\"article:published_time\" content=\"2025-02-28T10:46:18+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-05-06T07:51:53+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2025\/02\/Eisai-Enters-Into-License-Agreement-with-SciClone-for-Development-and-Commercialization-of-Tasulgratinib.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"800\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/webp\" \/>\n<meta name=\"author\" content=\"NewsDesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u57f7\u7b46\u8005\" \/>\n\t<meta name=\"twitter:data1\" content=\"NewsDesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"\u63a8\u5b9a\u8aad\u307f\u53d6\u308a\u6642\u9593\" \/>\n\t<meta name=\"twitter:data2\" content=\"2\u5206\" \/>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"\u30a8\u30fc\u30b6\u30a4\u3001SciClone\u793e\u306bTasulgratinib\u306e\u4e2d\u56fd\u306b\u304a\u3051\u308b\u30e9\u30a4\u30bb\u30f3\u30b9\u4f9b\u4e0e","description":"\u5f53\u793e\u306f\u3001SciClone Pharmaceuticals Limited\u3068\u3001\u30b3\u30cf\u30af\u9178\u30bf\u30b9\u30eb\u30b0\u30e9\u30c1\u30cb\u30d6\u306e\u72ec\u5360\u7684\u958b\u767a\u30fb\u8ca9\u58f2\u6a29\u3092\u8a31\u8afe\u3059\u308b\u5951\u7d04\u3092\u7de0\u7d50\u3057\u307e\u3057\u305f\u3002.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/itbusinesstoday.com\/ja\/health-tech\/eisai-enters-into-license-agreement-with-sciclone-for-development-and-commercialization-of-tasulgratinib-in-china-hong-kong-macau-and-taiwan\/","og_locale":"ja_JP","og_type":"article","og_title":"Eisai Licenses Tasulgratinib to SciClone for Greater China","og_description":"Eisai has signed an agreement with SciClone Pharmaceuticals Limited to grant exclusive rights to develop and sell tasulgratinib succinate.","og_url":"https:\/\/itbusinesstoday.com\/ja\/health-tech\/eisai-enters-into-license-agreement-with-sciclone-for-development-and-commercialization-of-tasulgratinib-in-china-hong-kong-macau-and-taiwan\/","og_site_name":"itbusinesstoday","article_published_time":"2025-02-28T10:46:18+00:00","article_modified_time":"2025-05-06T07:51:53+00:00","og_image":[{"width":1200,"height":800,"url":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2025\/02\/Eisai-Enters-Into-License-Agreement-with-SciClone-for-Development-and-Commercialization-of-Tasulgratinib.webp","type":"image\/webp"}],"author":"NewsDesk","twitter_card":"summary_large_image","twitter_misc":{"\u57f7\u7b46\u8005":"NewsDesk","\u63a8\u5b9a\u8aad\u307f\u53d6\u308a\u6642\u9593":"2\u5206"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/itbusinesstoday.com\/health-tech\/eisai-enters-into-license-agreement-with-sciclone-for-development-and-commercialization-of-tasulgratinib-in-china-hong-kong-macau-and-taiwan\/#article","isPartOf":{"@id":"https:\/\/itbusinesstoday.com\/health-tech\/eisai-enters-into-license-agreement-with-sciclone-for-development-and-commercialization-of-tasulgratinib-in-china-hong-kong-macau-and-taiwan\/"},"author":{"name":"NewsDesk","@id":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/#\/schema\/person\/d58d81f55e8acd257ab63d49fb4ea812"},"headline":"Eisai Enters Into License Agreement with SciClone for Development and Commercialization of Tasulgratinib in China, Hong Kong, Macau and Taiwan","datePublished":"2025-02-28T10:46:18+00:00","dateModified":"2025-05-06T07:51:53+00:00","mainEntityOfPage":{"@id":"https:\/\/itbusinesstoday.com\/health-tech\/eisai-enters-into-license-agreement-with-sciclone-for-development-and-commercialization-of-tasulgratinib-in-china-hong-kong-macau-and-taiwan\/"},"wordCount":265,"publisher":{"@id":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/#organization"},"image":{"@id":"https:\/\/itbusinesstoday.com\/health-tech\/eisai-enters-into-license-agreement-with-sciclone-for-development-and-commercialization-of-tasulgratinib-in-china-hong-kong-macau-and-taiwan\/#primaryimage"},"thumbnailUrl":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2025\/02\/Eisai-Enters-Into-License-Agreement-with-SciClone-for-Development-and-Commercialization-of-Tasulgratinib.webp","keywords":["Eisai","Pharma","SciClone","Tasulgratinib","tyrosine kinase inhibitor"],"articleSection":["Health Tech","International","News","Pharma"],"inLanguage":"ja"},{"@type":"WebPage","@id":"https:\/\/itbusinesstoday.com\/health-tech\/eisai-enters-into-license-agreement-with-sciclone-for-development-and-commercialization-of-tasulgratinib-in-china-hong-kong-macau-and-taiwan\/","url":"https:\/\/itbusinesstoday.com\/health-tech\/eisai-enters-into-license-agreement-with-sciclone-for-development-and-commercialization-of-tasulgratinib-in-china-hong-kong-macau-and-taiwan\/","name":"\u30a8\u30fc\u30b6\u30a4\u3001SciClone\u793e\u306bTasulgratinib\u306e\u4e2d\u56fd\u306b\u304a\u3051\u308b\u30e9\u30a4\u30bb\u30f3\u30b9\u4f9b\u4e0e","isPartOf":{"@id":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/#website"},"primaryImageOfPage":{"@id":"https:\/\/itbusinesstoday.com\/health-tech\/eisai-enters-into-license-agreement-with-sciclone-for-development-and-commercialization-of-tasulgratinib-in-china-hong-kong-macau-and-taiwan\/#primaryimage"},"image":{"@id":"https:\/\/itbusinesstoday.com\/health-tech\/eisai-enters-into-license-agreement-with-sciclone-for-development-and-commercialization-of-tasulgratinib-in-china-hong-kong-macau-and-taiwan\/#primaryimage"},"thumbnailUrl":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2025\/02\/Eisai-Enters-Into-License-Agreement-with-SciClone-for-Development-and-Commercialization-of-Tasulgratinib.webp","datePublished":"2025-02-28T10:46:18+00:00","dateModified":"2025-05-06T07:51:53+00:00","description":"\u5f53\u793e\u306f\u3001SciClone Pharmaceuticals Limited\u3068\u3001\u30b3\u30cf\u30af\u9178\u30bf\u30b9\u30eb\u30b0\u30e9\u30c1\u30cb\u30d6\u306e\u72ec\u5360\u7684\u958b\u767a\u30fb\u8ca9\u58f2\u6a29\u3092\u8a31\u8afe\u3059\u308b\u5951\u7d04\u3092\u7de0\u7d50\u3057\u307e\u3057\u305f\u3002.","breadcrumb":{"@id":"https:\/\/itbusinesstoday.com\/health-tech\/eisai-enters-into-license-agreement-with-sciclone-for-development-and-commercialization-of-tasulgratinib-in-china-hong-kong-macau-and-taiwan\/#breadcrumb"},"inLanguage":"ja","potentialAction":[{"@type":"ReadAction","target":["https:\/\/itbusinesstoday.com\/health-tech\/eisai-enters-into-license-agreement-with-sciclone-for-development-and-commercialization-of-tasulgratinib-in-china-hong-kong-macau-and-taiwan\/"]}]},{"@type":"ImageObject","inLanguage":"ja","@id":"https:\/\/itbusinesstoday.com\/health-tech\/eisai-enters-into-license-agreement-with-sciclone-for-development-and-commercialization-of-tasulgratinib-in-china-hong-kong-macau-and-taiwan\/#primaryimage","url":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2025\/02\/Eisai-Enters-Into-License-Agreement-with-SciClone-for-Development-and-Commercialization-of-Tasulgratinib.webp","contentUrl":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2025\/02\/Eisai-Enters-Into-License-Agreement-with-SciClone-for-Development-and-Commercialization-of-Tasulgratinib.webp","width":1200,"height":800,"caption":"Eisai"},{"@type":"BreadcrumbList","@id":"https:\/\/itbusinesstoday.com\/health-tech\/eisai-enters-into-license-agreement-with-sciclone-for-development-and-commercialization-of-tasulgratinib-in-china-hong-kong-macau-and-taiwan\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/itbusinesstoday.com\/"},{"@type":"ListItem","position":2,"name":"Eisai Enters Into License Agreement with SciClone for Development and Commercialization of Tasulgratinib in China, Hong Kong, Macau and Taiwan"}]},{"@type":"WebSite","@id":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/#website","url":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/","name":"\u30a4\u30c3\u30c8\u30d3\u30b8\u30cd\u30b9\u30c8\u30a5\u30c7\u30a4","description":"","publisher":{"@id":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"ja"},{"@type":"Organization","@id":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/#organization","name":"\u30a4\u30c3\u30c8\u30d3\u30b8\u30cd\u30b9\u30c8\u30a5\u30c7\u30a4","url":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/","logo":{"@type":"ImageObject","inLanguage":"ja","@id":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/#\/schema\/logo\/image\/","url":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2025\/01\/Asset-1.png","contentUrl":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2025\/01\/Asset-1.png","width":663,"height":275,"caption":"itbusinesstoday"},"image":{"@id":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/#\/schema\/person\/d58d81f55e8acd257ab63d49fb4ea812","name":"\u30cb\u30e5\u30fc\u30b9\u30c7\u30b9\u30af","image":{"@type":"ImageObject","inLanguage":"ja","@id":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2025\/01\/it.png74f313ad3d6fa27a1eee85c30be63d03","url":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2025\/01\/it.png","contentUrl":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2025\/01\/it.png","caption":"NewsDesk"},"sameAs":["https:\/\/itbusinesstoday.com"],"url":"https:\/\/itbusinesstoday.com\/ja\/author\/newsdesk\/"}]}},"authors":[{"term_id":205,"user_id":4,"is_guest":0,"slug":"newsdesk","display_name":"NewsDesk","avatar_url":{"url":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2025\/01\/it.png","url2x":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2025\/01\/it.png"},"0":null,"1":"","2":"","3":"","4":"","5":"","6":"","7":"","8":""}],"_links":{"self":[{"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/posts\/7008","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/comments?post=7008"}],"version-history":[{"count":2,"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/posts\/7008\/revisions"}],"predecessor-version":[{"id":10777,"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/posts\/7008\/revisions\/10777"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/media\/7044"}],"wp:attachment":[{"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/media?parent=7008"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/categories?post=7008"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/tags?post=7008"},{"taxonomy":"author","embeddable":true,"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/ppma_author?post=7008"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}